0.6801

2.84% -0.0199

After Hours: .70 0.0199 +2.93%

Palisade Bio Inc (PALI)

Overview News Price History Financials Discussions Forecast Stock Split

Palisade Bio Inc stock is traded at $0.6801, with a volume of 73,571. It is down -2.84% in the last 24 hours and down -8.34% over the past month. Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.

Previous Close:

$0.70

Open:

$0.69

24h Volume:

73,571

Relative Volume:

0.26

Market Cap:

$3.27M

Revenue:

Net Income/Loss:

$-14.07M

P/E Ratio:

-0.0486

EPS:

-13.99

Net Cash Flow:

$-12.56M

1W Performance:

-3.04%

1M Performance:

-8.34%

6M Performance:

-59.99%

1Y Performance:

-84.89%

1-Day Range:

$0.6609

$0.6999

1-Week Range:

$0.6609

$0.7427

52-Week Range:

$0.60

$4.89

Palisade Bio Inc Stock (PALI) Company Profile

Name

Palisade Bio Inc

Sector

Healthcare (1173)

Industry

Biotechnology (661)

Phone

(858) 704-4900

Address

7750 EL CAMINO REAL, SUITE 5200, CARLSBAD

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

PALI's Discussions on Twitter

Compare PALI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PALI Palisade Bio Inc	0.6801	3.27M	0	-14.07M	-12.56M	-13.99
VRTX Vertex Pharmaceuticals Inc	445.20	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	525.00	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	326.09	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	551.22	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	242.07	28.51B	3.81B	-644.79M	-669.77M	-6.24

Palisade Bio Inc Stock (PALI) Latest News

Jun 09, 2025

Ulcerative Colitis Drugs Market 2034: Clinical trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Therapies, Prevalence and Companies by DelveInsight - Barchart.com

Jun 09, 2025

Palisade Bio Inc (PALI)

Palisade Bio Inc Stock (PALI) Company Profile

Compare PALI with other stocks

Palisade Bio Inc Stock (PALI) Latest News

Ulcerative Colitis Drugs Market 2034: Clinical trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Therapies, Prevalence and Companies by DelveInsight - Barchart.com

Transpire Bio licenses rights to Intragrand’s PDE4 inhibitor ITG-1052 - BioWorld MedTech

GEN Restaurant Group, Inc. (NASDAQ:GENK) Shares Acquired by Northern Trust Corp - Defense World

Ameriprise Financial Inc. Sells 72,453 Shares of Eni S.p.A. (NYSE:E) - Defense World

The Wharf (Holdings) Limited (OTCMKTS:WARFY) Short Interest Up 27.0% in May - Defense World

Ameriprise Financial Inc. Sells 46,682 Shares of Brookfield Renewable Co. (NYSE:BEPC) - Defense World

Invesco S&P SmallCap Health Care ETF (NASDAQ:PSCH) Shares Purchased by Ameriprise Financial Inc. - Defense World

Yankuang Energy Group Company Limited (OTCMKTS:YZCAY) Short Interest Up 25.0% in May - Defense World

BOE Varitronix Limited (OTCMKTS:VARXF) Short Interest Update - Defense World

U.S. Global Jets ETF (NYSEARCA:JETS) Shares Sold by Ameriprise Financial Inc. - Defense World

Riverside Resources (OTCMKTS:RVSDF) Stock Price Down 9.3% – Should You Sell? - Defense World

Clune & Associates LTD. Invests $7.30 Million in Apple Inc. (NASDAQ:AAPL) - Defense World

5,157 Shares in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Bought by Northern Trust Corp - Defense World

Northern Trust Corp Raises Holdings in Key Tronic Co. (NASDAQ:KTCC) - Defense World

Ameriprise Financial Inc. Purchases New Position in Quantum Computing Inc. (NASDAQ:QUBT) - Defense World

Cetera Investment Advisers Purchases Shares of 70,006 Palisade Bio, Inc. (NASDAQ:PALI) - Defense World

Nuvation Bio’s (NUVB) “Market Outperform” Rating Reaffirmed at JMP Securities - Defense World

Ameriprise Financial Inc. Boosts Stake in BlackRock California Municipal Income Trust (NYSE:BFZ) - Defense World

Northern Trust Corp Acquires New Shares in iShares 10-20 Year Treasury Bond ETF (NYSEARCA:TLH) - Defense World

Torrid Holdings Inc. (NYSE:CURV) Shares Purchased by Bank of America Corp DE - Defense World

TPI Composites, Inc. (NASDAQ:TPIC) Shares Acquired by Bank of America Corp DE - Defense World

Cetera Investment Advisers Trims Stock Holdings in Royce Micro-Cap Trust, Inc. (NYSE:RMT) - Defense World

Palisade Bio Reports Improved Quarterly Losses - TipRanks

BNP Paribas Financial Markets Increases Position in Community West Bancshares (NASDAQ:CWBC) - Defense World

Palisade Bio (PALI) Reports Positive Phase 1 Results for PALI-21 - GuruFocus

Palisade Bio reports positive Phase 1 results for new drug By Investing.com - Investing.com South Africa

Palisade Bio Reports Positive Topline Data From Phase 1 Studies Of PALI-2108 - Nasdaq

Palatin Technologies (PALI) Teams Up with Key Managers for Inves - GuruFocus

Palisade Bio (PALI) Reports Positive Phase 1 Results for PALI-2108 | PALI Stock News - GuruFocus

Palatin Technologies (PALI) Teams Up with Key Managers for Investment Strategy | PALI Stock News - GuruFocus

Digital Ally, Inc. Sets Date to Discuss First Quarter 2025 Earnings Call Wednesday, May 28, 2025 at 11:15 a.m. Eastern Time - The Manila Times

Palisade Bio reports positive Phase 1 results for new drug - Investing.com

Palisade Bio Reports Positive Phase 1a Results for - GlobeNewswire

Breakthrough in Crohn's Disease Treatment: New Drug PALI-2108 Achieves Perfect Safety Profile in Phase 1 Trial - Stock Titan

Seneca Biopharma : Announces Update on Phase II Clinical Trial Underway in China for the Treatment of Ischemic Stroke - marketscreener.com

Biodexa Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:BDRX - Benzinga

Palisade Bio Q2 EPS Lifted by Brookline Capital Management - Defense World

Palisade Bio (NASDAQ:PALI) Earns “Buy” Rating from Brookline Capital Management - Defense World

Palisade Bio (PALI) Receives Buy Rating from Brookline Capital | - GuruFocus

Palisade Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView

Palisade Bio (PALI) Receives Buy Rating from Brookline Capital | PALI Stock News - GuruFocus

PALISADE BIO, INC. SEC 10-Q Report - TradingView

PALI stock plunges to 52-week low, touches $1.34 - MSN

Palisade Bio reports positive data for UC drug trial - MSN

Palisade Bio (PALI) Projected to Post Quarterly Earnings on Monday - Defense World

Palisade Bio’s PALI-2108 shows promise in ulcerative colitis study - Investing.com

PALI Reports Positive Preclinical Outcomes for Ulcerative Colitis Treatment | PALI Stock News - GuruFocus

Palisade Bio’s PALI-2108 shows promise in ulcerative colitis study By Investing.com - Investing.com Canada

Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases - GlobeNewswire

New Ulcerative Colitis Drug PALI-2108 Outperforms Standard Treatments in Crucial Disease Models - Stock Titan

Analyzing Palisade Bio (NASDAQ:PALI) and Ginkgo Bioworks (NYSE:DNA) - Defense World

Palisade Bio Inc Stock (PALI) Financials Data

Revenue

Net Income

Cash Flow

EPS

Palisade Bio Inc Stock (PALI) Insider Trading

Similar to PALI